HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Areti Georgopali Selected Research

Fidaxomicin

1/2020Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.
11/2019Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study.
6/2019Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
1/2019Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
12/2018Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE).
11/2018Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
1/2018Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Areti Georgopali Research Topics

Disease

8Clostridium Infections
01/2020 - 01/2017
3Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2019 - 11/2018
2Neoplasms (Cancer)
06/2019 - 01/2018
1Coinfection
11/2019
1Infections
01/2018

Drug/Important Bio-Agent (IBA)

7FidaxomicinIBA
01/2020 - 01/2018
4VancomycinFDA LinkGeneric
01/2020 - 01/2018
1EnzymesIBA
11/2019
1ImmunosorbentsIBA
11/2019
1TabletsIBA
01/2018
1Anti-Bacterial Agents (Antibiotics)IBA
01/2018
1Anti-Infective Agents (Microbicides)IBA
01/2017

Therapy/Procedure

1Aftercare (After-Treatment)
11/2019